S&P 500: 677.82 +0.8% NASDAQ 100: 607.32 +1.3% Dow Jones: 478.16 +0.6%

Stanley Druckenmiller’s ADMA Holdings & Trades

First Buy
Q4 2025
Duration Held
1 Quarters
Largest Add
Q4 2025
+252,200 Shares
Current Position
252,200 Shares
$4.6 M Value

Stanley Druckenmiller's ADMA Position Overview

Stanley Druckenmiller (via Duquesne Family Office LLC) currently holds 252,200 shares of ADMA Biologics, Inc. (ADMA) worth $4.6 M, representing 0.10% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Stanley Druckenmiller has initiated a new position in ADMA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Stanley Druckenmiller's ADMA Biologics (ADMA) Holding Value Over Time

Track share changes against reported price movement

Quarterly ADMA Biologics (ADMA) Trades by Stanley Druckenmiller

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +252,200 New Buy 252,200 $18.24

Stanley Druckenmiller's ADMA Biologics Investment FAQs

Stanley Druckenmiller first purchased ADMA Biologics, Inc. (ADMA) in Q4 2025, acquiring 252,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Stanley Druckenmiller has held ADMA Biologics, Inc. (ADMA) for 1 quarters since Q4 2025.

Stanley Druckenmiller's largest addition to ADMA Biologics, Inc. (ADMA) was in Q4 2025, adding 252,200 shares worth $4.6 M.

According to the latest 13F filing for Q4 2025, Stanley Druckenmiller's firm, Duquesne Family Office LLC, owns 252,200 shares of ADMA Biologics, Inc. (ADMA), valued at approximately $4.6 M.

As of the Q4 2025 filing, ADMA Biologics, Inc. (ADMA) represents approximately 0.10% of Stanley Druckenmiller's publicly disclosed stock portfolio, making it one of their key holdings.

Stanley Druckenmiller's peak holding in ADMA Biologics, Inc. (ADMA) was 252,200 shares, as reported at the end of Q4 2025.